A study finds that IN-006, a reformulated monoclonal antibody, is safe, well-tolerated, and delivers high antibody levels in the airway—offering a faster and more effective way to fight COVID-19.

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, ...

In the ongoing Omicron era, a new Covid-19 antibody could renew optimism for urgently required SARS-CoV-2 monoclonal therapies. Over the last three years, various ...

Some people vaccinated against COVID-19 initially acquire strong levels of neutralizing antibodies but then experience rapid declines. Measuring immunoglobulin A antibody titers post-vaccination could ...

Invivyd (NASDAQ:IVVD) said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody ...

PHILADELPHIA (WPVI) -- It's the only authorized treatment that can help keep people with COVID-19 out of the hospital, but hundreds-of-thousands of doses aren't being used. The effectiveness of ...

Researchers discover that the COVID-19 virus can trigger the production of 'abzymes' -- antibodies that act like enzymes -- which may explain why long COVID symptoms persist even after the infection ...

Researchers at the Institute of Human Virology (IHV) at the University of Maryland School of Medicine published a new study in the Journal of Infectious Diseases investigating the antibody response ...

In front of a basketball court, an A-frame sign reads “monoclonal antibody site” with arrows pointing to the right. Monoclonal antibodies were a common treatment for COVID-19 early in the pandemic.

Recently, scientists found that some people who suffered from COVID-19 had auto-antibodies targeting their own type 1 interferons, which are important immune signaling proteins. Now, researchers ...